Albireo Pharma (ALBO) Misses Q2 EPS by 27c

Albireo Pharma (NASDAQ: ALBO) reported Q2 EPS of ($1.22), $0.27 worse than the analyst estimate of ($0.95).

“The first half of 2018 was defined for Albireo by initiation of our Phase 3 program for A4250 in progressive familial intrahepatic cholestasis (PFIC),” said Ron Cooper, President and Chief Executive Officer of Albireo. “Notably, A4250 also received rare pediatric disease designation from the FDA, making Albireo eligible to apply for a priority review voucher upon submission of a new drug application for A4250. At the same time, we secured U.S. and E.U. method of use patents for elobixibat in the treatment of NASH, shared important findings on cholestatic liver disease at two scientific meetings, continued to strengthen our understanding of the cholestatic liver disease population and made key board and management appointments for our company.”

For earnings history and earnings-related data on Albireo Pharma (ALBO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15